BCMA Targeted CAR T-Cells is under clinical development by Shanghai YaKe Biotechnology and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BCMA Targeted CAR T-Cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BCMA Targeted CAR T-Cells overview
Gene therapy is under development for the treatment of relapsed and refractory multiple myeloma. It is administered through intravenous route. The therapy constitutes of genetically manipulated T cells which express a chimeric antigen receptor (CAR) targeting cells expressing tumor necrosis factor receptor superfamily member 17 (BCMA).
For a complete picture of BCMA Targeted CAR T-Cells’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.